Bipolar androgen therapy in castration-resistant prostate cancer: Biological rationale, clinical evidence, and future directions.

Rival PM, Jiang J, Qu LG, O'Brien J, Gilmore P, Corcoran N

Open source

DOI
10.1097/cu9.0000000000000374
Published
2026 Nov
Container
Current urology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/cu9.0000000000000374,
  title = {Bipolar androgen therapy in castration-resistant prostate cancer: Biological rationale, clinical evidence, and future directions.},
  author = {Rival PM and Jiang J and Qu LG and O'Brien J and Gilmore P and Corcoran N},
  year = {2026},
  journal = {Current urology},
  doi = {10.1097/cu9.0000000000000374},
  url = {https://doi.org/10.1097/cu9.0000000000000374}
}

RIS

TY  - JOUR
TI  - Bipolar androgen therapy in castration-resistant prostate cancer: Biological rationale, clinical evidence, and future directions.
AU  - Rival PM
AU  - Jiang J
AU  - Qu LG
AU  - O'Brien J
AU  - Gilmore P
AU  - Corcoran N
PY  - 2026
JO  - Current urology
DO  - 10.1097/cu9.0000000000000374
UR  - https://doi.org/10.1097/cu9.0000000000000374
ER  - 

APA

PM, R., J, J., LG, Q., J, O., P, G., & N, C. (2026). Bipolar androgen therapy in castration-resistant prostate cancer: Biological rationale, clinical evidence, and future directions.. Current urology. https://doi.org/10.1097/cu9.0000000000000374

Source records